Acute hepatitis due to fluoxetine therapy.
Fluoxetine-induced hepatotoxicity is generally considered of minimal clinical importance and is not well recognized. Asymptomatic increases in liver enzyme values have been observed in 0.5% of patients who take long-term fluoxetine therapy. This report details 2 cases of acute hepatitis believed to be caused by fluoxetine. Three cases of acute hepatitis caused by fluoxetine have been reported previously. The mechanism of fluoxetine-induced hepatotoxicity is unknown. Although routine monitoring of liver function may not be cost-effective, physicians should be alert to the possibility of fluoxetine-associated hepatitis and consider early discontinuation of the drug if this condition is suspected.
Department of General Internal Medicine, Marshfield Clinic, Wis. 54449, USA.
Q
Q
Cai
M A
MA
Benson
T J
TJ
Talbot
G
G
Devadas
H J
HJ
Swanson
J L
JL
Olson
J P
JP
Kirchner
D000208:Acute Disease; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000175:diagnosis* / Q000209:etiology*; D003937:Diagnosis, Differential; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D000410:Alanine Transaminase; D018687:Antidepressive Agents, Second-Generation; D001219:Aspartate Aminotransferases; D001663:Bilirubin; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors